🔍

Avience Biomedicals Limited (AVIENCE)

📊 NSE: AVIENCE 🏢 Medical Equipment & Supplies 📢 Latest filing: 16 Sep 2026

Latest quarterly results (H2 FY26)

In its latest reported quarter, H2 FY26, Avience Biomedicals' revenue was ₹25.7 Cr, and net profit ₹4.2 Cr; the operating margin was 29.9%.

H2 FY26 (₹ Cr)	Value	YoY	vs prev. half
Revenue	₹25.7	—	—
Operating profit	₹7.7	—	—
Net profit	₹4.2	—	—
EPS (₹)	10.45	—	—
Operating margin	29.9%	—	—

Full quarterly financials → Results calendar →

AVIENCE delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 74.55% of the AVIENCE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 67.1%. That is close to its usual level. Turnover was only ₹88 lakh, so a handful of trades can move this figure. Volume was 0.5 times its average, well below normal. It closed at its lower price band (circuit) on 16 Oct, one of 4 band closes in about the last 20 sessions.

74.55%Delivery, 16 Oct

67.1%Own 20-session average

0.5×Volume vs its average

₹266.90NSE close · -3.65%

Delivery in the last 5 sessions: 75.0% · 66.3% · 75.0% · 57.4% · 74.5%

Delivery across the market →Circuit stocks →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Avience Biomedicals Schedules 7th AGM for September 30, 2026; E-Voting Cut-Off September 23

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 16 Sep 2026, 07:29 PM

Avience Biomedicals Limited has announced that its 7th Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 11:30 AM via Video Conferencing. The cut-off date to determine shareholder eligibility for e-voting is set as Wednesday, September 23, 2026. The remote e-voting window will run from September 26, 2026 (9:00 AM) to September 29, 2026 (5:00 PM). Additionally, the register of members and share transfer books will remain closed from September 24 to September 30, 2026.

7th Annual General Meeting scheduled for Wednesday, September 30, 2026, at 11:30 AM via VC/OAVM
Cut-off date for e-voting entitlement fixed as Wednesday, September 23, 2026
Remote e-voting window opens September 26, 2026 (9:00 AM) and closes September 29, 2026 (5:00 PM)
Book closure period set from September 24, 2026 to September 30, 2026 (both days inclusive)

💡 Eligible shareholders holding shares as of September 23, 2026, can participate in remote e-voting and review resolutions in the FY2025-26 Annual Report.

Avience Biomedicals Dispatches AGM Notice Letters to Shareholders Without Registered Emails

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Sep 2026, 11:24 PM

Avience Biomedicals Limited has issued letters to shareholders whose email addresses are not registered with the Company, RTA, or Depository Participants pursuant to Regulation 36(1)(b) of SEBI LODR Regulations. The communication provides weblinks to access the Annual General Meeting (AGM) notice and the Annual Report. The company reported a net profit of Rs 4.215 crore on revenue of Rs 25.69 crore in the quarter ended March 2026. This announcement is purely compliance-related with no direct financial impact.

Compliance under Regulation 36(1)(b) of SEBI LODR Regulations, 2015
Letters sent specifically to shareholders lacking registered email IDs with depositories
AGM Notice and Annual Report links hosted on official website www.avienbio.com
Company posted March 2026 quarterly revenue of Rs 25.6865 crore and net profit of Rs 4.215 crore

💡 Shareholders without registered email addresses should review the AGM notice on the company website and ensure depository details are updated to receive future corporate communications directly.

Avience Biomedicals Convenes 7th AGM; Seeks Approval for Borrowing Limit up to ₹100 Crore

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 08 Sep 2026, 12:15 PM

Avience Biomedicals has issued the notice for its 7th Annual General Meeting scheduled for September 30, 2026. The company is seeking shareholder approval under Section 180(1)(c) to increase borrowing powers up to ₹100 crore, significantly higher than its current debt of ₹19 crore and net worth of ₹27 crore. Additionally, the agenda includes the appointment of M/s M.A.M AND ASSOCIATES as statutory auditors, replacing M/s HARIBHAKTI & CO. LLP, for a 5-year term until the 12th AGM.

7th Annual General Meeting scheduled for September 30, 2026, at 11:30 AM via VC/OAVM
Special resolution proposed to enhance borrowing limits up to ₹100,00,00,000 (₹100 crore)
Appointment of M/s M.A.M AND ASSOCIATES as statutory auditors in place of retiring auditor M/s HARIBHAKTI & CO. LLP
Appointments of Secretarial and Internal Auditors proposed for a 5-year tenure (FY 2026-27 to FY 2030-31)

💡 Track voting outcomes of the AGM on September 30, 2026, particularly regarding the ₹100 crore borrowing limit and future debt utilization plans.

Avience Biomedicals Convenes 7th AGM; Seeks Approval for Rs 100 Cr Borrowing Limit

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 08 Sep 2026, 11:18 AM

Avience Biomedicals Limited has issued notice for its 7th Annual General Meeting scheduled for September 30, 2026. The key special resolution seeks shareholder approval under Section 180(1)(c) to increase borrowing powers up to Rs 100 crore, compared to its existing net worth of Rs 27 crore and debt of Rs 19 crore. Additionally, the company proposed the appointment of M/s M.A.M AND ASSOCIATES as statutory auditors to succeed M/s Haribhakti & Co. LLP, alongside regular director re-appointments.

7th Annual General Meeting to be held on September 30, 2026 via Video Conferencing
Approval sought under Section 180(1)(c) to expand borrowing limits up to Rs 100,00,00,000 (Rs 100 crore)
Proposed borrowing limit of Rs 100 crore represents ~3.7x the company's net worth of Rs 27 crore
Appointment of M/s M.A.M AND ASSOCIATES as Statutory Auditors in place of retiring auditors M/s Haribhakti & Co. LLP

💡 Track voting results of the AGM on September 30, 2026, and monitor any subsequent debt-raising announcements or capex plans tied to the expanded borrowing limit.

Avience Biomedicals to Hold 7th AGM on Sept 30, 2026; Recommends New Statutory Auditor

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 07 Sep 2026, 06:51 PM

Avience Biomedicals Limited has scheduled its 7th Annual General Meeting for September 30, 2026, with the book closure period set between September 24 and September 30, 2026. The Board has recommended appointing M/s. M.A.M AND ASSOCIATES as Statutory Auditors for a 5-year term (FY 2026-27 to 2030-31) in place of retiring auditors Haribhakti & Co. LLP. Additionally, the Board approved seeking shareholder approval for borrowing powers and asset charge creation under Sections 180(1)(c) and 180(1)(a) of the Companies Act, 2013.

07th AGM scheduled for September 30, 2026 via video conference.
Book closure fixed from September 24, 2026 to September 30, 2026.
Recommended M.A.M AND ASSOCIATES as Statutory Auditors for 5 consecutive FYs (2026-27 to 2030-31).
Recommended V C A N & CO LLP as Internal Auditors for 5 consecutive FYs (2026-27 to 2030-31).
Board approved agenda item to enhance borrowing powers and mortgage/charge creation under Section 180 of the Companies Act.

💡 Track shareholder voting results post the September 30, 2026 AGM and check the full AGM notice for specific limits proposed under the Section 180 borrowing resolution.

Avience Biomedicals revises FY26 results to rectify ₹337.55 lakh inter-company balance error

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 26 Aug 2026, 12:06 AM

Avience Biomedicals Limited has released revised audited consolidated financial results for the year ended March 31, 2026. The revision corrects an inadvertent Excel link error in results originally adopted on July 16, 2026, which caused an overstatement of both Other Current Liabilities and Short-term Loans and Advances by ₹337.55 lakhs due to un-eliminated inter-company balances. The company confirmed the correction has zero impact on reported consolidated profit, net assets, or total equity. Additionally, the Board appointed M/s. G.R. Gupta & Associates as Secretarial Auditor for a 5-year term (FY 2026-27 to FY 2030-31) and approved sitting fees of ₹1,000 per meeting for Independent/Non-Executive Directors.

Revised FY26 consolidated balance sheet to eliminate ₹337.55 lakh inter-company balance error
Zero financial impact on consolidated net profit, total equity, or net assets as of March 31, 2026
Appointed M/s. G.R. Gupta & Associates as Secretarial Auditor for 5 consecutive financial years (FY27 to FY31)
Approved sitting fees of ₹1,000 per meeting for Independent/Non-Executive Directors effective July 1, 2026

💡 Track the filing of the revised annual report and watch for shareholder approval of the secretarial auditor at the upcoming Annual General Meeting.

Avience Biomedicals Submits Quarterly Share Dematerialization Certificate for June 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Jul 2026, 08:41 PM

Avience Biomedicals Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The document, provided by the Registrar and Share Transfer Agent (Skyline Financial Services), confirms the processing of share dematerialization requests for the quarter ended June 30, 2026. This process includes the verification, mutilation, and cancellation of physical certificates and updating the depository as the registered owner. This is a standard procedural filing required for all listed entities to ensure accurate shareholding records.

Quarterly compliance for the period ended June 30, 2026
Confirmation of dematerialization by RTA Skyline Financial Services Private Limited
Adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

💡 This is a routine administrative filing; investors should focus on upcoming financial results or material business developments instead.

Avience Biomedicals Reports Non-Applicability of SEBI Corporate Governance Provisions for Q1 FY27

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 29 Jul 2026, 08:30 PM

Avience Biomedicals Limited has filed a compliance report for the quarter ended June 30, 2026, stating that specific SEBI Corporate Governance regulations are not applicable to it. As the company is listed on the NSE Emerge (SME) platform, it is exempt from Regulations 17 through 27 under Regulation 15(2)(b) of SEBI LODR. This is a routine procedural filing supported by a certificate from a Practicing Company Secretary. Such exemptions are standard for SME-listed entities to reduce the administrative compliance burden.

Exemption claimed under Regulation 15(2)(b) of SEBI (LODR) Regulations, 2015 for the quarter ended June 30, 2026
Exemptions apply to Regulations 17, 17A, 18, 19, 20, 21, 22, 24, 24A, 25, 26, 26A, and 27
Certificate confirming non-applicability issued by G.R. Gupta & Associates dated July 29, 2026
Company remains listed on the SME Platform of NSE (NSE Emerge)

💡 No action is required as this is a routine administrative filing. Investors should monitor for any future plans to migrate to the Main Board, which would necessitate full compliance with these governance standards.

Avience Biomedicals Files Regulation 74(5) Compliance for Quarter Ended June 30, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Jul 2026, 08:20 PM

Avience Biomedicals Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing confirms that for the quarter ended June 30, 2026, the company's Registrar and Share Transfer Agent (RTA), Skyline Financial Services Private Limited, processed all share dematerialization requests. This process includes the mutilation and cancellation of physical share certificates and updating the depository as the registered owner. This is a standard administrative filing with no impact on the company's financial position or business operations.

Compliance confirmed for the quarter ended June 30, 2026
Certificate issued by Registrar and Share Transfer Agent, Skyline Financial Services Private Limited
Verification of dematerialization, mutilation, and cancellation of physical share certificates
Filing submitted to the National Stock Exchange on July 29, 2026

💡 No action is required as this is a routine regulatory filing. Investors should focus on upcoming quarterly financial results for material business updates.

60% Growth Guidance for FY27 and ₹47 Cr Order Book for Avience Biomedicals

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 28 Jul 2026, 11:38 PM

Avience Biomedicals reported FY26 revenue of ₹52.51 cr, a 16% YoY increase, with PAT growing 23.31% to ₹8.75 cr. Management has provided a strong growth guidance of at least 60% for FY27, aiming to exceed ₹100 cr in revenue, backed by a current order book of ₹47 cr. A new manufacturing facility is slated to become operational in October 2026, which is expected to enable participation in larger government tenders and boost export capabilities. The company maintains a high-margin profile with EBITDA margins improving to 28.45% in FY26.

FY26 Revenue increased to ₹52.51 cr from ₹45.24 cr in FY25, with EBITDA margins expanding to 28.45%.
Current order book stands at approximately ₹47 cr, representing nearly 90% of FY26 total revenue.
Management targets minimum 60% revenue growth for FY27, with potential to cross the ₹100 cr mark.
New manufacturing facility completion is targeted for September 2026 with production starting in October.
Exports target set at ₹5-7 cr for the current year, with ₹70-80 lakh already achieved in the first quarter.

💡 Monitor the timely commissioning of the new manufacturing facility in October 2026 and the conversion of the ₹47 cr order book into revenue during H2 FY27.

Avience Biomedicals Reports FY26 Net Profit of 1,246.58 vs 976.88 YoY; Capex at 1,344.86

🟢 POSITIVE ⭐ 6/10

EARNINGS 📅 27 Jul 2026, 02:31 PM

Avience Biomedicals reported a net profit (before tax) of 1,246.58 for the year ended March 31, 2026, up from 976.88 in the previous year. The company demonstrated improved operational efficiency with net cash from operations rising to 590.62 from 339.43 YoY. A significant capital expenditure of 1,344.86 was recorded for property, plant, and equipment, indicating aggressive expansion. As an SME-listed entity, the company remains exempt from certain corporate governance disclosures and continues to report under Indian GAAP.

Net profit before tax grew to 1,246.58 in FY26 from 976.88 in FY25
Net cash generated from operating activities increased by 74% to 590.62
Substantial investment in property, plant, and equipment totaling 1,344.86 during the year
Cash and cash equivalents decreased to 227.47 from 421.98 due to high investing activities
Statutory auditors issued an unmodified audit opinion for the financial year

💡 Investors should monitor the revenue contribution from the new 1,344.86 capex in the medical devices segment and track the management of trade receivables, which saw a 410.41 increase during the year.

View All AVIENCE Announcements on Live Market Tracking →